These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 38851606)
1. Fabrication of chitosan-based emulsion as an adjuvant to enhance nasal mucosal immune responses. Li D; Li W; Li S; Zhang Y; Hu X; Liu S; Li Y Int J Biol Macromol; 2024 Jun; 272(Pt 2):132913. PubMed ID: 38851606 [TBL] [Abstract][Full Text] [Related]
2. Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice. Shahiwala A; Amiji MM J Drug Target; 2008 May; 16(4):302-10. PubMed ID: 18446609 [TBL] [Abstract][Full Text] [Related]
3. Curdlan sulfate- Zhang S; Huang S; Lu L; Song X; Li P; Wang F Int J Nanomedicine; 2018; 13():2377-2394. PubMed ID: 29713168 [TBL] [Abstract][Full Text] [Related]
4. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. Bento D; Staats HF; Gonçalves T; Borges O Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119 [TBL] [Abstract][Full Text] [Related]
5. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza. Gupta NK; Tomar P; Sharma V; Dixit VK Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration. Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271 [TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization. Liu Q; Zhang C; Zheng X; Shao X; Zhang X; Zhang Q; Jiang X Vaccine; 2014 May; 32(22):2582-90. PubMed ID: 24681230 [TBL] [Abstract][Full Text] [Related]
8. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Ishii M; Kojima N Glycoconj J; 2010 Jan; 27(1):115-23. PubMed ID: 19816665 [TBL] [Abstract][Full Text] [Related]
9. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Patel GB; Zhou H; Ponce A; Chen W Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279 [TBL] [Abstract][Full Text] [Related]
10. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. Slütter B; Jiskoot W J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405 [TBL] [Abstract][Full Text] [Related]
11. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response. Pawar D; Jaganathan KS Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494 [TBL] [Abstract][Full Text] [Related]
12. Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine. Lin X; Sheng Y; Zhang X; Li Z; Yang Y; Wu J; Su Z; Ma G; Zhang S J Control Release; 2022 Jun; 346():380-391. PubMed ID: 35483639 [TBL] [Abstract][Full Text] [Related]
14. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. Patel GB; Ponce A; Zhou H; Chen W J Liposome Res; 2008; 18(2):127-43. PubMed ID: 18569448 [TBL] [Abstract][Full Text] [Related]
15. Chrysanthemum sporopollenin: A novel vaccine delivery system for nasal mucosal immunity. Liu J; Yan XD; Li XQ; Du YH; Zhu LL; Ye TT; Cao ZY; Dong ZW; Li ST; Xu X; Bai W; Li D; Zhang JW; Wang SJ; Li SH; Sun J; Yin XZ Front Immunol; 2023; 14():1132129. PubMed ID: 36845130 [TBL] [Abstract][Full Text] [Related]
16. Chitosan stabilized nasal emulsion delivery system for effective humoral and cellular response against recombinant tetravalent dengue antigen. Vemireddy S; M C PP; Halmuthur M SK Carbohydr Polym; 2018 Jun; 190():129-138. PubMed ID: 29628230 [TBL] [Abstract][Full Text] [Related]
17. Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes. Chen L; Zhu J; Li Y; Lu J; Gao L; Xu H; Fan M; Yang X PLoS One; 2013; 8(8):e71953. PubMed ID: 23977186 [TBL] [Abstract][Full Text] [Related]
18. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant. Campos EA; Namikoshi J; Maeba S; Yamamoto M; Fukumoto M; Yamamoto H J Oral Sci; 2003 Mar; 45(1):25-31. PubMed ID: 12816361 [TBL] [Abstract][Full Text] [Related]
19. [Preparation of chitosan hydrochloride stabilized emulsion and its immunostimulatory effect]. Wang D; Wu J; Wang N Sheng Wu Gong Cheng Xue Bao; 2023 Jan; 39(1):262-274. PubMed ID: 36738215 [TBL] [Abstract][Full Text] [Related]
20. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. Arias MA; Van Roey GA; Tregoning JS; Moutaftsi M; Coler RN; Windish HP; Reed SG; Carter D; Shattock RJ PLoS One; 2012; 7(7):e41144. PubMed ID: 22829921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]